Wednesday, May 22, 2019
CURE Pharmaceutical, an innovative drug delivery and development company, announced the issuance of U.S. Patent No. 10,307,397, which covers the high load of bioactive cannabinoid molecules integrated into oral thin film dosage forms. The cannabinoids include cannabidiol (CBD) and tetrahydrocannabinol (THC).
Advances in drug delivery are critical to improving cannabis-based products,” said Rob Davidson, CEO of CURE Pharmaceutical. “This patent secures a critical advantage – the ability to deliver high loads of cannabinoid active molecules with an oral thin film for optimal efficacy and dosing frequency.”
A higher load in oral thin film means 30 percent or more of the cannabinoid molecule is integrated. So, for example, 30mg of cannabidiol (CBD) for a 100mg film. This is meaningful for CBD, as higher doses are often desirable for optimal effect on the endocannabinoid system.
CURE has vertical research and manufacturing operations registered with the DEA to develop and manufacture cannabis-derived and synthetic cannabidiol-based products using its CUREfilm™ technology at its facility in Oxnard, Calif. With CUREfilm, the delivery of cannabinoids is easier and more effective as it offers increased bioavailability, ease and precision of dosing and greater palatability.
Source: Company Press Release
Key Facts
Online pharmacies now enable men everywhere to purchase cheap Kamagra online: Value for Money One of Visit Website viagra sales in australia the major causes of sexual disorders. Apart from improving stamina, strength and sex power, pharmacy canada cialis these herbal male stamina enhancer supplements also offer effective cure for premature ejaculation. The medicine is considered as the counterpart of traditionally used amerikabulteni.com viagra price blue pills before the launch of Kamagra. cheap viagra usa Keeping the popularity, its safety and efficacy profile in view, the answer is yes.